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Abstract: Uses of peptides in medicine are limited by low membrane 
permeability, metabolic instability, high clearance rates and 
negligible oral bioavailability. Predicting oral bioavailability of 
drugs relies on physicochemical properties that favor passive 
permeability and oxidative metabolic stability, but these may not be 
appropriate for peptides. Here we investigate effects of heterocyclic 
constraints, intramolecular hydrogen bonds and shielding 
sidechains on oral bioavailability of cyclic heptapeptides. NMR-
derived solution structures, amide H-D exchange rates and 
temperature dependent chemical shifts showed that rigidification, 
stronger hydrogen bonds, and solvent shielding by bulky branched 
sidechains combined to enhance oral bioavailability for these cyclic 
heptapeptides in rats.  
Peptides are a rich natural source of chemical diversity that is 
under-exploited in medicine, principally because they are 
metabolically unstable and too polar for intestinal absorption or 
plasma retention after oral ingestion.[1] Cyclization makes peptides 
more stable to proteolytic enzymes, such as aminopeptidases and 
carboxypeptidases that cleave off amino acids from their N- and C-
termini respectively and digestive proteases in the GI tract that 
recognize and hydrolyse extended strand-like peptide 
conformations.[2] Nature modifies cyclic peptides for enhanced 
membrane permeability by reducing hydrogen-bond donors (e.g. by 
replacing NH with N-methyl, N-heterocycle, or O) and by 
minimizing water solvation of amides (e.g. by forming transannular 
hydrogen bonds or shielding polar atoms using hydrophobic side 
chains). These are the reasons for the atypical oral bioavailability of 
the 11-residue cyclic peptide natural product drug cyclosporin A,[3] 
which is conformationally flexible and exists in multiple 
conformations in solution.[4] This flexibility reportedly inspired the 
discovery of an orally bioavailable synthetic cyclic hexapeptide.[5a] 
However, there have been surprisingly few reports of cyclic peptides 
that have been rationally modified in order to enhance both 
membrane permeability and oral bioavailability.[5] Here we set out to 
use three dimensional solution structural information to design 
changes to a marine natural product, the cyclic heptapeptide 
sanguinamide A,[6] in order to increase intestinal permeability and 
oral bioavailability. This approach may be valuable in understanding 
key principles for rationally designing orally bioavailable peptides.  
Simple head-to-tail cyclization of Ile-Ala-Ala-Phe-Pro-Ile-Pro to 
a cyclic heptapeptide (1, Figure 1) was first examined to understand 
how further constraints can influence the structure and oral 
absorption of sanguinamide A (2, Figure 2) and analogues. NMR 
spectra for 1 revealed the presence of two conformers (1a, 1b) 
arising from cis-trans isomerization at Ile5-Pro6 and a cis-amide at 
Phe3-Pro4. This equilibrium is not uncommon for cyclic peptides 
containing proline and/or N-methyl amino acids. Unlike cyclosporin 
A, which adopts interconverting conformations in solution, cis-trans 
isomers of 1 have high energetic barriers to interconversion.  
Figure 1. Cyclo-[Ile-Ala-Ala-Phe-Pro-Ile-Pro] (1) and its 600 MHz 
1
H-
NMR spectrum (amide region) in d6-DMSO. Two sets of amide 
protons are due to cis-3/4, trans-5/6 (1a) and cis-3/4, cis-5/6 (1b) 
isomers (ratio 2:1 respectively). 
 We have previously reported the total synthesis of 
sanguinamide A, cyclo-[Ile(Thz)-Ala-Phe-Pro-Ile-Pro] (2, Figure 
2), a thiazole-containing cyclic peptide analogue of 1 isolated from 
the sea slug H. sanguineus.[6] It features all L-amino acids, 
phenylalanine, alanine, isoleucine, two prolines, and an isoleucine-
thiazole dipeptide surrogate. The latter heterocycle helps rigidify the 
cyclic peptide 2, which adopts a single conformation with only one 
cis-amide (Phe3-Pro4). This conformation has two strong 
intramolecular hydrogen bonds between Ala2 and Leu5 (Figure 2). 
It has molecular properties that are both expected (hydrogen bond 
donors (HBD) = 4, rotatable bonds (RotB) = 6) and not expected 
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(MW = 721, hydrogen bond acceptors (HBA) = 13, calculated 
partition coefficient (CLogP) = 5.5, topological polar surface area 
(tPSA) = 169Å2)[7] to favor oral bioavailability, yet compound 2 
exhibited some bioavailability after oral delivery at 10 mg/kg to 
male Wistar rats (F = 7%, Cmax 40 nM, Tmax 60 min), despite 
rapid clearance (70 mL/min/kg) and a short half-life (t1/2  23 min).
[6] 
Oral availability of 2 is attributed to (a) three heterocycles replacing 
three amide NH protons in a heptapeptide, reducing HBD by three; 
(b) shielding of several polar atoms from water by hydrophobic side 
chains (Ile1, Pro4, Ile5, Pro6); and (c) two intramolecular hydrogen 
bonds (Ala2 NH…OC Ile5, Ala2 CO…HN Ile5) that force polar 
atoms to the interior of the macrocycle. We now propose further 
changes designed to decrease solvent exposure of its polar surface in 
order to increase membrane permeability and oral bioavailability.  
Figure 2. Sanguinamide A (2) showing A) molecular structure, B) 
NMR-derived solution structure (d6-DMSO) and C) solvent-exposed 
surface, with hydrogen bonds (dashed lines), amide NH nitrogens 
(cyan), and two exposed amide NH protons (black circles). 
 
Of the four amide NH protons in 2, only two are solvent-
exposed (Ala2, Phe3) and visible on the surface shown above (cyan, 
Figure 2) of the NMR-derived solution structure for 2 in d6-DMSO. 
We set out to N-methylate the more exposed Phe3 NH, thereby 
reducing the H-bond donor count in 2 to three. Despite the Ala2 NH 
of 2 being hydrogen bonded, according to a characteristically low 
temperature-dependent chemical shift (/T = -2.9 ppb/deg)[8] and 
three dimensional structure analysis indicating that it projects into 
the interior of the macrocycle to form a H-bond with the Ile5 CO,[6] 
we find that H-D exchange of Ala2 is still relatively fast (Table 1) 
consistent with some degree of solvent exposure. We therefore 
sought to shield this amide bond. We hypothesized that changing 
Ala2, to the bulkier residue tBuGly2 (tert-butyl glycine) with a 
branched hydrophobic sidechain, might block solvation of the amide 
NH at position 2. Together, the two changes, Ala2 to tBuGly and 
Phe3 to N-Me-Phe3 resulted in new cyclic peptide, danamide D (3, 
Figure 3) which was readily synthesized by solid phase synthesis 
(Suppl Material) following the total synthesis of sanguinamide A.[6] 
Figure 3. Danamide D (3) showing A) molecular structure, B) NMR-
derived solution structure (d6-DMSO) and C) solvent-exposed surface, 
hydrogen bonds (dashed lines) and amide NH nitrogen atoms (cyan). 
To test whether this strategy was successful, 1D 1H-NMR 
experiments were conducted to compare H-D amide exchange rates 
and temperature-dependent amide NH chemical shifts for residues in 
2 versus 3 (Table 1). Replacing Ala2 in 2 with the bulkier tert-butyl 
glycine resulted in a much slower H-D exchange and a very small 
effect of temperature on chemical shift of this amide NH (Table 1). 
These data strongly suggest minimal solvent exposure of this amide 
NH, which we ascribe to efficient masking by the tert-butyl 
sidechain in 3. For both 2 and 3, the Ile5 NH had a very slow H-D 
exchange rate and the NMR temperature coefficient for this amide 
NH decreased to -1.6 ppb/K, indicating that the Ala2 CO…HN Ile5 
intramolecular hydrogen bond had not been disrupted. Shielding of 
the Ile1(Thz) NH was likewise maintained in the Ile5-Pro6-
Ile1(Thz) segment, with little change in H-D exchange rate and only 
a small change in the NMR temperature coefficient.  
Table 1. H-D exchange rates (90% d6-DMSO, 10% D2O) and NMR 
temperature coefficients (d6-DMSO) for amide NH protons of 2-4. 
        a
 See reference
[6]
. 
The solution structure was determined for 3 in d6–DMSO at 
298 K using NOESY 2D 1H NMR spectra, calculated from 41 NOE 
distance restraints, two backbone -dihedral angle restraints derived 
from 3JNH-CH, one cis-amide between Phe3-Pro4, and without any 
hydrogen bond restraints. Structures were calculated in XPLOR-
NIH[9a] using a dynamic simulated annealing protocol in a geometric 
force field and energy minimized using the CHARMm force 
field.[9b]  The 20 lowest energy structures (Figures 3B, 5A) for 3 
had no distance (≥ 0.2 Å) or dihedral angle (≥ 2°) violations and 
were quite rigid, convergent structures (ave. pairwise backbone 
RMSD 0.180 Å). The structure for 3 supported observations made in 
the VT NMR and H-D exchange experiments (Table 1), with 
reciprocal tBuGly2 CO…HN Ile5 and tBuGly2 NH…OC Ile5 
hydrogen bonds forming an antiparallel -sheet connected by a 
hairpin turn centered at Phe3-Pro4 (Figure 3A). Pro6 and Ile1(Thz) 
form an -turn[10] at the other end of 3. Side chains from Pro4-Ile5-
Pro6-Ile1 create a contiguous hydrophobic surface along one side of 
the molecule (Figure 3C), which shields polar atoms in Ile1 and 
Ile5 from solvent. Incorporating the bulky tert-butyl substituent 
almost but not completely masks the amide proton and carbonyl 
oxygen of tBuGly2 and slightly masks the carbonyl oxygen of Phe3, 
making these polar atoms less accessible to solvent. The Phe3 NH of 
2 was removed by N-methylation, reducing the barrier to rotation 
around tBuGly2-Phe3 to produce two conformations (Figure 5A 
and B). The common Pro4-Ile5-Pro6 motif in 2 and 3 is also present 
in other natural products (e.g. dichotomin G,[11a] phakellistatin 1,[11b] 
6,[11c] 10, [11d] 17,[11e] 18,[11e] stylopeptide 1,[11f] stylisin 2[11g]) and 
may be one way that Nature shields the amide backbone to create a 
contiguous hydrophobic patch (Fig. 2, 3) that may be important in 
peptides for membrane permeability (see ahead). 
Cyclic Peptide:    2
a 
   3   4 
Amide NH                               H-D exchange t1/2 (min, 298K) 
Ile1(Thz)  1500  1400 2000 
Ala2 or tBuGly2  188  5600 21000 
Phe3  380 - 387 
Ile5 6000 5500 15000  
 
Amide NH                      Temperature coefficient /T (ppb/K) 
Ile1(Thz)  -4.0 -2.9 -2.9 
Ala2 or tBuGly2 -2.9 -0.3 0.005 
Phe3 -4.2 - -3.9 
Ile5 -4.0 -1.6 -1.8 
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The exposed polar surface has therefore been minimized in 
progressing from 2 to 3 by removing and shielding solvent 
accessible amide NHs. However, these modifications did not affect 
the intramolecular hydrogen bonds, with the exception of residue 2 
where shielding dampened H-D exchange. The amide NH of Ile5 
suffered a slight but noticeable increase in H-D exchange rate in 
changing from structure 2 to 3. We wondered whether amide N-
methylation at Phe3, while reducing the number of hydrogen bond 
donors, might have disrupted the structure by slightly shifting the 
tert-butyl substituent and weakening the hydrogen bond. Although 
H-D exchange rates and NMR temperature coefficients (Table 1) 
did not indicate any pronounced increase in flexibility, NMR-
structure calculations did suggest more flexibility at the Phe3 
residue in 3 versus 2, after the N-methyl group had been introduced. 
This encouraged us to investigate the structure of the non-N-
methylated analogue of 3, namely 4 (Figure 4).  
Figure 4. Danamide F (4) showing: A) molecular structure, B) NMR-
derived solution structure (d6-DMSO) and C) solvent-exposed surface. 
Dashed lines are hydrogen bonds, amide NH nitrogen atoms in cyan.  
 
The solution structure was determined for 4 in d6–DMSO at 298 
K using NOESY 2D 1H NMR spectra, calculated from 34 NOE 
distance restraints, four backbone –dihedral angle restraints 
derived from 3JNH-CH, one cis-amide between Phe3-Pro4, and 
without any hydrogen bond restraints. The 20 lowest energy 
structures (Figure 4B and 5A) for 4 had no distance (≥0.2 Å) or 
dihedral angle (≥2°) violations and were very rigid, convergent 
structures (ave. pairwise backbone RMSD 0.041 Å). The structure 
of 4 was subtly different from 3, the tBu substituent now completely 
masked the amide protons of tBuGly2 and Ile5 (Figure 4C), making 
them less accessible to solvent. Structural differences between 3 and 
4 were visualized in more detail by superimposing the 20 lowest 
energy NMR-solution structures of each compound (Figure 5). 
Backbone RMSD indicated less conformational flexibility about the 
Phe3-Pro4 bond and the Ile5-Pro6-Ile1(Thz)-tBuGly2 segment in 4 
than 3 (Figure 5A), suggesting a more rigid backbone structure in 4 
than in 3. The higher flexibility in 3 resulted in weaker 
intramolecular hydrogen bonds between tBuGly2 and Ile5 in the 20 
lowest energy structures, measured as changes in phi and psi angles 
at Phe3 and Ile5 (Figure 5B) and distances between hydrogen 
bonding atoms (Figure 5C). Although the phi and psi angles were 
quite different among the 20 lowest energy structures of 3 (Figure 
5B, left), they did not change much and were more clustered in the 
20 lowest energy structures of 4 (Figure 5B, right). Likewise, the H-
bond N…O and H…O distances for Ile5 NH…OC tBuGly2 were 
quite varied for 3 (Figure 5C, left) but did not change across the 20 
structures of 4 (Figure 5C, right). These findings were in good 
agreement with surface comparisons of amides in 3 vs 4 (Figure 3 
vs 4).  
This evidence for decreased conformational flexibility in the 
cyclic peptide backbone upon changing from 3 (RMSD 0.18Å) with 
an N-Me-Phe3 to compound 4 (RMSD 0.04Å) with a Phe3, are 
strongly supported by H-D exchange rates and VT NMR 
temperature coefficients (Table 1). There was a three fold slower H-
D exchange of tBuGly2 NH and Ile5 NH in 4 than in 3, while the 
temperature dependence of the chemical shift for the tBuGly2 amide 
NH was diminished. These data are consistent with much stronger 
tBuGly2 NH…OC Ile5 and tBuGly2 CO…HN Ile5 hydrogen bonds 
in 4 than 3. The reintroduced Phe3 NH had a similar H-D exchange 
rate to Phe3 in 2. We conclude that a steric clash between N-Me of 
Phe3 and tBu of tBuGly2, and a lower tBuGly2-Phe3 amide bond 
rotational energy, in 3 slightly altered the conformational ensemble 
and increased structural flexibility, whereas no such clash occurs in 
4 and so the tBu more effectively protects the two amide NH…OC 
pairs and creates a more contiguous hydrophobic patch than in 3.      
Figure 5. A: Superimposition of 20 lowest energy solution structures 
of 3 and 4 with backbone atom pairwise RMSD of 0.18Å and 0.04Å 
respectively, double arrow line indicates flexibility at Phe3 N-
methylated amide; B: Phi and Psi dihedral angles for Phe3 (square) 
and Ile5 (triangle) for 3 (left) vs 4 (right); C: the H-bond N...O and 
N…H distances for Ile5-NH…OC-tBuGly2 in 3 (left) vs 4 (right). 
 
Finally, we investigated how these structural changes in 2, 3 
and 4 affected membrane permeability, oral bioavailability and other 
pharmacokinetic parameters. Experimental polar surface areas 
(ePSA)[12] determined for 1 (77 Å2), 2 (74 Å2), 3 (64 Å2) and 4 (70 
Å2) correlated well with experimental RRCK[13] cell membrane 
permeabilities (Papp (cm.s-1) 0.6 x 10-6, 1; 0.7 x 10-6, 2; 9.6 x 10-6, 
3; 1.2 x 10-6, 4) but neither correlated with the rank order of oral 
bioavailability (Figure 6, Table 2), which is also influenced by 
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other factors like solubility, metabolic clearance and protein 
binding. Cyclic peptides 3 and 4 were administered to male Wistar 
rats (10 mg/kg p.o. vs. 1 mg/kg i.v.) under conditions we reported 
previously[6] for sanguinamide A (2). We found that predictions 
made about solvent exposure from NMR studies of amide H-D 
exchange (Table 1), of shielding of polar amides observed in NMR 
solution structures (Figures 3, 4), and of hydrogen bond strengths 
based on measured distances in solution (e.g. Figure 5), correlated 
well with oral bioavailabilities of 3 and 4 (Figure 6). Compound 3 
exhibited an improved pharmacokinetic profile compared to 
sanguinamide A (2) with 3-fold improvements in oral 
bioavailability (F%) and half life (t1/2), 25 fold increases in area 
under the curve (AUC0-8 h) and maximum plasma concentration 
(Cmax), and a 6-fold decrease in clearance from plasma (Table 2).  
Figure 6. Plasma concentrations vs. time for cyclic peptide 3 (A) and 
4 (B) after administration of 10 mg/kg p.o. in olive oil (squares) vs. 1 
mg/kg i.v. in DMSO (circles) to male Wistar rats measured by LC-MS.  
Table 2. Pharmacokinetic data for 2, 3, 4 and cyclosporin A (10 
mg/kg/p.o. in olive oil vs 1mg/kg/i.v. in DMSO) to male Wistar
a
 rats.  
Entry t1/2 
(min) 
CL  
(mL/min/
kg) 
Cmax  
(ng/mL) 
Tmax 
(min) 
AUC
b
 
(ng.h/ 
mL) 
   F% 
2
c
 23 70.0 13.9 60 92   7 ± 4 
3 65 12.5 352 240 2647 21 ± 2 
51 ± 9 4 97 23.0 726 240 3372 
CSA
d
 153 8.6 763 240 4095 21 ± 3 
a
For 2, n=4 (p.o), n=4 (i.v.). For 3, n=6 (p.o.), n=4 (i.v.). For 4, n=4 
(p.o.) n=3 (i.v.). 
b
p.o. 10mg/kg. 
c
Reference 6. 
d
Reported values for 
CSA in rats are 10 mg/kg i.v. vs. 10 mg/kg p.o., AUC 13800 ng.h/mL 
(p.o.), F% 29;
[14a]
 and 6 mg/kg i.v. vs. 10 mg/kg p.o., AUC 5500 
ng.h/mL (p.o.), F% 23.
[14b]
 
 
Surprisingly, removing the N-Me in 3 to produce 4 more than 
doubled oral bioavailability (F%), increasing AUC, Cmax, t1/2 but 
also doubling clearance (CL). All compounds lie well outside 
traditional orally bioavailable small molecule space: 1 (MW = 709, 
HBD = 5, “HBA” = 14, CLogP = 5.8, RotB = 6, tPSA = 186Å2), 2 
(MW = 721, HBD = 4, “HBA” = 14, CLogP = 5.5, RotB = 6, tPSA 
= 169Å2), 3 (MW = 778, HBD = 3, “HBA” = 13, CLogP = 7.4, 
RotB = 7, tPSA = 161Å2) and 4 (MW = 764, HBD = 4, “HBA” = 
13, CLogP = 6.8, RotB = 7, tPSA = 169Å2). Indeed, all have 
multiple violations of Lipinski[7] and Veber[15] parameters and 
provide new information on oral bioavailability limits for peptides. 
 
In conclusion, we have transformed a cyclic heptapeptide 1, 
which exists in multiple conformers, to a more rigid scaffold by the 
introduction of a planar heterocycle (thiazole), two intramolecular 
hydrogen bonds, and a compact branched (tert-butyl glycine) amino 
acid sidechain that shields both H-bonds and polar atoms in 3 and 4. 
These additional constraints lead to measurable oral absorption and 
oral bioavailability in rats. Rather than relying upon traditional 
guidelines for improving pharmacokinetic properties, such as rule-
of-five, in silico calculations and membrane permeability assays, our 
study progressed solely based on NMR observations (in particular 
amide H-D exchange rates, solution structures and solvent exposed 
polar surfaces) to guide structural modifications for enhancing oral 
bioavailability. These results demonstrate that NMR-guided studies 
could be valuable in optimizing oral bioavailability of cyclic 
peptides. To our knowledge this is the first reported study where 
oral bioavailability has been rationally optimized solely on the basis 
of NMR spectroscopic observations of solvent exposed surfaces. 
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